1. Discovery of a Potent, Orally Active 11β-Hydroxysteroid Dehydrogenase Type 1 Inhibitor for Clinical Study: Identification of (S)-2-((1S,2S,4R)-Bicyclo[2.2.1]heptan-2-ylamino)-5-isopropyl-5-methylthiazol-4(5H)-one (AMG 221)
2. 2-Amino-1,3-thiazol-4(5H)-ones as Potent and Selective 11β-Hydroxysteroid Dehydrogenase Type 1 Inhibitors: Enzyme−Ligand Co-Crystal Structure and Demonstration of Pharmacodynamic Effects in C57Bl/6 Mice
3. Fotsch, C.; Adams, J.; Bartberger, M.; Bercot, E. A.; Cai, L.; Castro, V. M.; Chen, M.; Cupples, R.; Emery, M.; Fretland, J.; Guram, A.; Gustafsson, S.; Hague, A.; Hale, C.; Han, N.; Hayashi, M.; Henriksson, M.; Hickman, D.; Homan, E.; Hungate, R. W.; Johansson, L.; Jordan, S.; Kaiser, C.; Komorowski, R.; Li, A.; Liu, Q.; Matsumoto, G.; McRae, K.; Moniz, G.; Palm, G.; Pyring, D.; St. Jean, D. J., Jr.; Sun, Y.; Sydow-Backman, M.; Tedenborg, L.; Tu, H.; Ursa, S.; Veniant, M.; Williams, M.; Xu, G.; Ye, Q.; Yuan, C.; Zhang, J.; Zhang, X.; Wang, M. Abstracts of Papers, 237th ACS National Meeting, Salt Lake City, UT, March 22–26, 2009; MEDI-029.
4. Construction of chiral quaternary carbon centers by asymmetric alkylation of achiral lithium enolates mediated by chiral tetradentate ligands: Stoichiometric and catalytic approaches